In a new note to investors on April 25, an analyst has provided a rating update for the Healthcare company, Canopy Growth Corporation (WEED). On April 25, analyst John Chu gave a Hold rating to WEED and set a C$74 price target.
According to TipRanks.com, Chu is ranked #3719 out of 5199 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Canopy Growth Corporation with a C$77.86 average price target.
Based on Canopy Growth Corporation’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of C$67.58 million. In comparison, last year the company had a GAAP net loss of C$61.54 million.
Canopy Growth Corp. engages in the production and sale of medical cannabis. The company offers products including oils and concentrates, soft gel capsules, and hemp. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite.
The company’s shares closed on Tuesday at C$68.38.
